- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02329808
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics (PROTECT)
Clinical Validation of a Dried Blood Spot (DBS) Method for the Analysis of Immunosuppressive and Antifungal Drugs in Pediatric Patients (Part of the PROTECT Study).
This is a clincial validation study of a dried blood spot (DBS) method for the analysis of immunosuppressive and antifungal agents currently subject of therapeutic drug monitoring (TDM) in a pediatric population.
The primary goal is to clinically validate a finger prick DBS method compared to conventional venous sampling for the analysis of 5 immunosuppressive and 4 azole antifungal drugs in the pediatric population. Secondairy goals include feasibility of the finger prick DBS method in the target population, to design an inventory of costs that will be incurred in future health-economic analyses and to construct a population PK model based on the available data collected for the primariy goal.
Study Overview
Status
Intervention / Treatment
Detailed Description
Therapeutic drug monitoring (TDM) offers the possibility to individualize and improve a patient's pharmacological treatment, based on the measurement of drug concentrations in biological samples. Conventionally, TDM is performed with blood or plasma obtained by venous blood sampling. This method is associated with several challenges such as i) the need for the patient to travel to the hospital or health center; ii) special conditions for sample transport to guarantee stability of the analyte and to decrease the biohazard risk; iii) sampling times not always representing the preferable peak or trough concentrations; iv) the method being invasive and v) delay of the outcome of the analyses with regard to the outpatient visit.
The Dried Blood Spot (DBS) may offer a solution for all these challenges. DBS is thought to offer benefits over plasma venous sampling for TDM. The main purpose of the PROTECT (Personalized treatment of immunosuppressive and antifungal drugs through continuous home based monitoring with Dried Blood Spot sampling techniques in pediatric patients) study is to improve therapeutic management and patient participation in pediatric patients treated with antifungal and immunosuppressive agents. PROTECT is mainly financed by a ZonMW grant 'Goed Gebruik Geneesmiddelen'.
Four patient organizations are actively involved in the PROTECT study.
Objective of the study:
Primairy To clinically validate a finger prick DBS method compared to conventional venous sampling for the analysis of 5 immunosuppressive and 4 azole antifungal drugs in the pediatric population. Secondairy
- Feasibility of the novel finger prick DBS method in the pediatric population will be assessed. This includes scoring of relevant characteristics (attributes) of blood drawing methods for TDM, evaluation of the experience and attitude of both patients and parents regarding finger prick DBS sampling and evaluation of the understanding of the written instructions provided for performing the finger prick at home. The data obtained in this validation study will be used for the implementation of the DBS in therapeutic drug monitoring (TDM) being a less invasive procedure, and as a base for a discrete choice-experiment as part of the HTA.
- To design an inventory of types of costs that will be incurred in the process of DBS-based and conventional TDM as a preparation step for later health economic analysis.
- Data from this study will be used to construct a population pharmacokinetic model to optimize dosing and design new guidelines.
This is an observational mono-centre study in which DBS sampling is compared with conventional sampling for TDM in a steady state situation.
Clearly, information on feasibility of DBS sampling in children and on costs relevant to DBS sampling in children can only be obtained through actual sampling in children.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands
- Radboud University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients aged between 2 and 18 years
- Admitted to the Radboudumc pediatric ward
- Having a venous catheter
- Treated with at least 1 of the 9 drugs of interest
- The drug concentration being at steady state
- Signed informed consent
Exclusion Criteria:
- Parents and/or patients are not able to understand the Dutch language
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Mycophenolic acid
Patients treated for their regular patient care with mycophenolic acid.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Cyclosporin
Patients treated for their regular patient care with cyclosporin.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Tacrolimus
Patients treated for their regular patient care with tacrolimus.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Sirolimus
Patients treated for their regular patient care with sirolimus.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Everolimus
Patients treated for their regular patient care with everolimus.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Voriconazole
Patients treated for their regular patient care with voriconazole.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Posaconazole
Patients treated for their regular patient care with posaconazole.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Itraconazole+metabolite
Patients treated for their regular patient care with itraconazole.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
Fluconazole
Patients treated for their regular patient care with fluconazole.
|
The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
drug concentration
Time Frame: predose, 2 samples postdose, max 6 hours post dose
|
The outcome measure is a composite of several blood concentrations, obtained by three individual blood drawing moments per patient.
The related endpoint is the evaluation of the association between the concentration obtained by venous sampling and the concentration obtained by means of DBS sampling.
The predictive performance of the DBS method as a measure for the venous concentration will be evaluated.
|
predose, 2 samples postdose, max 6 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionnaire
Time Frame: 1 day
|
The related endpoint is the response to a questionnaire.
Results will be used to prepare implementation of the novel method for home-based monitoring as well as to prepare a HTA analysis.
|
1 day
|
costs
Time Frame: 2 years
|
Costs of blood drawing methods will be collected.The cost types will function as a basis for future HTA analysis of this novel sampling method compared to conventional venous sampling.
|
2 years
|
Area under the curve
Time Frame: 6h period
|
Blood concentrations will be used to calculate the area under the concentration time curve (AUC).
The outcome measure will be a composite of population estimates of the pharmacokinetic parameters AUC, maximal concentration (Cmax), time to maximal concentration (Tmax), clearance (CL), volume of distribution (Vd) and elimination half-life (t1/2).
|
6h period
|
Collaborators and Investigators
Investigators
- Principal Investigator: Roger Bruggemann, PharmD PhD, Radboud University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMCN-AKF 14.02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of North Carolina, Chapel HillLantheus Medical ImagingCompletedChronic Kidney Diseases | Cystic Kidney DiseaseUnited States
-
SanofiTerminatedCongenital Cystic Kidney DiseaseGermany, Spain, United States, Australia, Belgium, Japan, Korea, Republic of, Netherlands
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Pang PengGuangdong Provincial Hospital of Traditional Chinese MedicineUnknownEnd-Stage Kidney Disease | Chronic Kidney FailureChina
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
RenJi HospitalUnknownKidney Diseases,CysticChina
-
George Washington UniversityCareDx; VirginiaBio Analytics, LLCTerminatedKidney Diseases | Kidney Failure, Chronic | Kidney Transplant Infection | Kidney Transplant Rejection | Kidney Injury | Kidney Disease, Chronic | Kidney Failure | Kidney Failure, Acute | Kidney Transplant; Complications | Kidney IschemiaUnited States
-
Renibus Therapeutics, Inc.CompletedKidney Failure, AcuteUnited States
-
Emory UniversityNorthwestern University; Columbia University; Satellite Healthcare; Norman S. Coplon...CompletedKidney Failure, Chronic | Kidney Transplantation | End-Stage Kidney DiseaseUnited States
Clinical Trials on blood drawing
-
Radboud University Medical CenterRecruitingAortic Valve Stenosis | Aortic Valve DiseaseNetherlands
-
Abant Izzet Baysal UniversitySelcuk UniversityCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Singapore Cancer Syndicate.TerminatedGastrointestinal CancerSingapore
-
Tel-Aviv Sourasky Medical CenterUnknownAttention-Deficit/Hyperactivity DisorderIsrael
-
National Taiwan University HospitalUnknown
-
Fudan UniversityUnknownProstate Cancer MetastaticChina
-
Migal Galilee Research InstituteZiv Medical CenterUnknownType I DiabetesIsrael
-
Eastern Hepatobiliary Surgery HospitalGuangzhou Burning Rock Bioengineering Co., LtdRecruitingBiliary Tract CancerChina
-
Mahidol UniversityIcahn School of Medicine at Mount Sinai; Samitivej Hospital groupCompleted